709 related articles for article (PubMed ID: 25904241)
21. Prevention of cardiovascular events with antiplatelet treatment: does time of intake matter for aspirin and ADP receptor blockers?
Sibbing D; Gross L; Aradi D
Thromb Haemost; 2016 Jan; 115(1):3-6. PubMed ID: 26334227
[TBL] [Abstract][Full Text] [Related]
22. Human platelet protease-activated receptor-1 responsiveness to thrombin related to P2Y12 inhibition.
Badr Eslam R; Lang IM; Kaider A; Panzer S
Transl Res; 2013 May; 161(5):414-20. PubMed ID: 23313628
[TBL] [Abstract][Full Text] [Related]
23. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
[TBL] [Abstract][Full Text] [Related]
24. Platelet Inhibition Agents: Current and Future P2Y12 Receptor Antagonists.
Tang J; Li MP; Zhou HH; Chen XP
Curr Vasc Pharmacol; 2015; 13(5):566-77. PubMed ID: 25440595
[TBL] [Abstract][Full Text] [Related]
25. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition.
Björkman JA; Zachrisson H; Forsberg GB; von Bahr H; Hansson GI; Warner TD; Nylander S
Thromb Res; 2013 Apr; 131(4):313-9. PubMed ID: 23419412
[TBL] [Abstract][Full Text] [Related]
26. Platelet P2Y
Amoafo EB; Entsie P; Kang Y; Canobbio I; Liverani E
Br J Pharmacol; 2024 Feb; 181(4):532-546. PubMed ID: 37525937
[TBL] [Abstract][Full Text] [Related]
27. Universal versus platelet reactivity assay-driven use of P2Y12 inhibitors in acute coronary syndrome patients: cost-effectiveness analyses for six European perspectives.
Coleman CI; Limone BL
Thromb Haemost; 2014 Jan; 111(1):103-10. PubMed ID: 24136466
[TBL] [Abstract][Full Text] [Related]
28. A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia.
Kiers D; van der Heijden WA; van Ede L; Gerretsen J; de Mast Q; van der Ven AJ; El Messaoudi S; Rongen GA; Gomes M; Kox M; Pickkers P; Riksen NP
Thromb Haemost; 2017 Aug; 117(9):1798-1807. PubMed ID: 28692111
[TBL] [Abstract][Full Text] [Related]
29. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
[TBL] [Abstract][Full Text] [Related]
30. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse.
Totani L; Dell'Elba G; Martelli N; Di Santo A; Piccoli A; Amore C; Evangelista V
Thromb Haemost; 2012 Jun; 107(6):1130-40. PubMed ID: 22436970
[TBL] [Abstract][Full Text] [Related]
31. P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
Liu F; Tantry US; Gurbel PA
Expert Opin Pharmacother; 2015 Jun; 16(8):1149-65. PubMed ID: 25873127
[TBL] [Abstract][Full Text] [Related]
32. Utility of the Aspirin and P2Y12 Response Assays to Determine the Effect of Antiplatelet Agents on Platelet Reactivity in Traumatic Brain Injury.
Parry PV; Choi PA; Bauer JS; Panczykowski DM; Puccio AM; Okonkwo DO
Neurosurgery; 2017 Jan; 80(1):92-96. PubMed ID: 28362884
[TBL] [Abstract][Full Text] [Related]
33. High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials.
Trenk D; Kristensen SD; Hochholzer W; Neumann FJ
Thromb Haemost; 2013 May; 109(5):834-45. PubMed ID: 23238773
[TBL] [Abstract][Full Text] [Related]
34. G-protein-coupled receptors signaling pathways in new antiplatelet drug development.
Gurbel PA; Kuliopulos A; Tantry US
Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):500-12. PubMed ID: 25633316
[TBL] [Abstract][Full Text] [Related]
35. Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer.
Gareau AJ; Brien C; Gebremeskel S; Liwski RS; Johnston B; Bezuhly M
Clin Exp Metastasis; 2018 Feb; 35(1-2):25-35. PubMed ID: 29322294
[TBL] [Abstract][Full Text] [Related]
36. Genetic Variant in Human PAR (Protease-Activated Receptor) 4 Enhances Thrombus Formation Resulting in Resistance to Antiplatelet Therapeutics.
Tourdot BE; Stoveken H; Trumbo D; Yeung J; Kanthi Y; Edelstein LC; Bray PF; Tall GG; Holinstat M
Arterioscler Thromb Vasc Biol; 2018 Jul; 38(7):1632-1643. PubMed ID: 29748334
[TBL] [Abstract][Full Text] [Related]
37. New anti-platelet agents: the end of resistance?
Kastrati A
Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663
[TBL] [Abstract][Full Text] [Related]
38. Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion.
Cooke NM; Spillane CD; Sheils O; O'Leary J; Kenny D
BMC Cancer; 2015 Sep; 15():627. PubMed ID: 26353776
[TBL] [Abstract][Full Text] [Related]
39. Apolipoprotein B100 danger-associated signal 1 (ApoBDS-1) triggers platelet activation and boosts platelet-leukocyte proinflammatory responses.
Assinger A; Wang Y; Butler LM; Hansson GK; Yan ZQ; Söderberg-Nauclér C; Ketelhuth DF
Thromb Haemost; 2014 Aug; 112(2):332-41. PubMed ID: 24816772
[TBL] [Abstract][Full Text] [Related]
40. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
